Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP167 in adults with homozygous familial hypercholesterolemia
CTR20260080Phase 2Active
- Sponsor
- Eddingpharm
- Start
- Feb 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of EDP167 in familial hypercholesterolemia (FH) (2 arms), sponsored by Eddingpharm. Primary endpoint: Percent change from baseline in serum LDL-C at Week 24 (main study). Started Feb 2026; status: active.
02
Drugs
EDP167
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20260080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260080.